ArriVent BioPharma, Inc.
We are a Phase 3 clinical biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. (Incorporated in Delaware) We seek to utilize our team’s deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline […]
January 7, 2024 Read More